(E)-3-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (E)-3-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-enamide
• 化学式: C₁₆H₁₃N₃O
• 分子量: 263.29
• InChiKey: LIKICCHRPIHREJ-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.8
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES
  申请人：Confluence Life Sciences, Inc.

  公开号：US20150210705A1

  公开（公告）日：2015-07-30

  Disclosed herein are substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions useful in the treatment of TAK mediated diseases, such as cancer, having the structure of Formula (I): wherein R 1 , R 2 , R 3 , and R 4 are as defined in the detailed description. Methods of modulation of TAK activity in a human or animal subject are also provided, providing therapeutic benefit to subjects with disease conditions, especially cancer.

  本文披露了一种替代吡咯吡啶和吡咯吡嗪化合物及其组成物，在治疗TAK介导的疾病，如癌症方面有用，其结构为式(I)：其中R1、R2、R3和R4如详细说明中定义的那样。还提供了在人类或动物受体中调节TAK活性的方法，为患有疾病状况的受体提供治疗益处，特别是癌症。
• SUBSTITUTED PYROOLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES
  申请人：Confluence Life Sciences, Inc.

  公开号：EP3096761A1

  公开（公告）日：2016-11-30
• US9499551B2
  申请人：——

  公开号：US9499551B2

  公开（公告）日：2016-11-22
• [EN] SUBSTITUTED PYROOLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES<br/>[FR] PYRROLOPYRIDINES ET PYRROLOPYRAZINES SUBSTITUÉES POUR TRAITER LE CANCER OU LES MALADIES INFLAMMATOIRES
  申请人：CONFLUENCE LIFE SCIENCES INC

  公开号：WO2015112854A1

  公开（公告）日：2015-07-30

  Disclosed herein are substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions useful in the treatment of TAK mediated diseases, such as cancer, having the structure of Formula (I): wherein R1, R2, R3, and R4 are as defined in the detailed description. Methods of modulation of TAK activity in a human or animal subject are also provided, providing therapeutic benefit to subjects with disease conditions, especially cancer.